The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Mars, Incorporated and VCA Inc.; Analysis To Aid Public Comment Proposed Consent Agreement
20171764: Berkshire Fund IX, L.P.; Advanced Drainage Systems, Inc.
20171791: Verizon Communications Inc.; WideOpenWest, Inc.
20171825: Corvex Master Fund LP; Envision Healthcare Corporation
20171861: TPG Partners VII, LP; Greenbriar Equity Fund III, L.P.
20171862: Cannae Holdings, Inc.; J. Alexander's Holdings, Inc.
Total Wine & More
20171838: PayPal Holdings, Inc.; Swift Financial Corporation
20171880: Republic Services, Inc.; RE Community Holdings, LP
FOIA Request
Response to Requester
Consumer Complaints July 19, 2017 through September 5, 2017 Match.com
Grifols, S.A., and Talecris Biotherapeutics Holdings Corp., In the Matter of
The FTC required Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. It resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws. As part of the settlement, Grifols will sell the Talecris fractionation facility in Melville, New York, and Grifols’ plasma collection centers in Mobile, Alabama, and Winston-Salem, North Carolina, to Kedrion S.p.A. Kedrion is a manufacturer of plasma-derived products in Europe and other markets, and will be a new entrant in the U.S. plasma-derived products industry. Grifols also will manufacture three plasma-derived products for Kedrion for several years under a manufacturing agreement. The FTC approved a final order on July 22, 2011.